City of Hope National Medical Center, Duarte, CA.
JCO Oncol Pract. 2024 Nov;20(11):1471-1480. doi: 10.1200/OP.24.00230. Epub 2024 Nov 12.
Until the early 2000s, advanced or metastatic non-small cell lung cancer (NSCLC) was treated as a single disease with all histologic subtypes treated alike with standard chemotherapy agents. Over the past two decades, the treatment paradigms for advanced NSCLC have changed dramatically with the discovery of multiple targeted therapies that are now approved for the treatment of NSCLC tumors with specific oncogene drivers or molecular alterations. Molecular testing has become integrated and critical for the clinical management of advanced NSCLC. The discovery and success of these targeted therapies have reshaped the classification of NSCLC on the basis of molecular classification and enabled a personalized approach in thoracic oncology. In this review, we discuss recent developments in the molecular profiling of NSCLC, and approved and emerging targeted therapies for the treatment of NSCLC.
直到 21 世纪初，晚期或转移性非小细胞肺癌（NSCLC）被视为一种单一疾病，所有组织学亚型都采用标准化疗药物进行相同的治疗。在过去的二十年中，随着多种靶向治疗药物的发现，晚期 NSCLC 的治疗模式发生了巨大变化，这些药物现在已被批准用于治疗具有特定致癌基因驱动因素或分子改变的 NSCLC 肿瘤。分子检测已成为晚期 NSCLC 临床管理的重要组成部分。这些靶向治疗的发现和成功改变了基于分子分类的 NSCLC 分类，并在胸部肿瘤学中实现了个性化治疗方法。在这篇综述中，我们讨论了 NSCLC 分子谱分析的最新进展，以及批准和新兴的用于治疗 NSCLC 的靶向治疗药物。
